138 related articles for article (PubMed ID: 20332442)
1. Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer.
Landt S; Jeschke S; Koeninger A; Thomas A; Heusner T; Korlach S; Ulm K; Schmidt P; Blohmer JU; Lichtenegger W; Sehouli J; Kuemmel S
Anticancer Res; 2010 Feb; 30(2):375-81. PubMed ID: 20332442
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
Kaura B; Bagga R; Patel FD
J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
[TBL] [Abstract][Full Text] [Related]
3. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of angiogenin (ANG) in invasive cervical cancer and in cervical intraepithelial neoplasia (CIN).
Bodner-Adler B; Hefler L; Bodner K; Leodolter S; Frischmuth K; Kainz C; Mayerhofer K
Anticancer Res; 2001; 21(1B):809-12. PubMed ID: 11299848
[TBL] [Abstract][Full Text] [Related]
5. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients.
Fatela-Cantillo D; Fernandez-Suarez A; Moreno MA; Gutierrez JJ; Iglesias JM
Tumour Biol; 2012 Jun; 33(3):825-32. PubMed ID: 22231432
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
Sidorkiewicz I; Zbucka-Krętowska M; Zaręba K; Lubowicka E; Zajkowska M; Szmitkowski M; Gacuta E; Ławicki S
BMC Cancer; 2019 Apr; 19(1):398. PubMed ID: 31035945
[TBL] [Abstract][Full Text] [Related]
8. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.
Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R
Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543
[TBL] [Abstract][Full Text] [Related]
9. [The significance of TU M2-PK tumor marker for lung cancer diagnostics].
Oremek G; Kukshaĭte R; Sapoutzis N; Ziolkowski P
Klin Med (Mosk); 2007; 85(7):56-8. PubMed ID: 17882813
[TBL] [Abstract][Full Text] [Related]
10. Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer.
Kuemmel S; Thomas A; Landt S; Fuger A; Schmid P; Kriner M; Blohmer JU; Sehouli J; Schaller G; Lichtenegger W; Köninger A; Fuchs I
Anticancer Res; 2009 Feb; 29(2):641-5. PubMed ID: 19331214
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of heat shock protein 90
Han S; Cheng Z; Zhao X; Huang Y
J Int Med Res; 2019 Nov; 47(11):5518-5525. PubMed ID: 31426690
[TBL] [Abstract][Full Text] [Related]
12. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors.
Staib P; Hoffmann M; Schinköthe T
Clin Chem Lab Med; 2006; 44(1):28-31. PubMed ID: 16375581
[TBL] [Abstract][Full Text] [Related]
14. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
16. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
17. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients.
Porika M; Vemunoori AK; Tippani R; Mohammad A; Bollam SR; Abbagani S
Asian Pac J Cancer Prev; 2010; 11(6):1745-7. PubMed ID: 21338226
[TBL] [Abstract][Full Text] [Related]
18. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected].
Mathur SP; Mathur RS; Gray EA; Lane D; Underwood PG; Kohler M; Creasman WT
Gynecol Oncol; 2005 Sep; 98(3):467-83. PubMed ID: 15982726
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.
Sheng X; Du X; Zhang X; Li D; Lu C; Li Q; Ma Z; Song Q; Wang C
Croat Med J; 2009 Oct; 50(5):455-64. PubMed ID: 19839069
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of post-radiation serum squamous cell carcinoma antigen and primary tumor regression for cervical squamous cell carcinoma.
Wan Q; Yan W; Liu Y; Lin Y; Lu Z
Cancer Biomark; 2020; 29(3):327-335. PubMed ID: 32716344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
